123 related articles for article (PubMed ID: 25459122)
1. Biotherapies of neuromuscular disorders.
Briand JF; Roy MO; Mourlane F; André C; Loux N; Rougeau C; Toursel T; Braun S
Rev Neurol (Paris); 2014 Dec; 170(12):799-807. PubMed ID: 25459122
[TBL] [Abstract][Full Text] [Related]
2. Gene-based therapies of neuromuscular disorders: an update and the pivotal role of patient organizations in their discovery and implementation.
Braun S
J Gene Med; 2013; 15(11-12):397-413. PubMed ID: 24123726
[TBL] [Abstract][Full Text] [Related]
3. Biotherapies for Parkinson disease.
Remy P
Rev Neurol (Paris); 2014 Dec; 170(12):763-9. PubMed ID: 25459116
[TBL] [Abstract][Full Text] [Related]
4. [Biotherapy targeting the immune system].
Frenzel L
Rev Prat; 2015 Jan; 65(1):12-20. PubMed ID: 25842417
[TBL] [Abstract][Full Text] [Related]
5. Biotherapies in stroke.
Detante O; Jaillard A; Moisan A; Barbieux M; Favre IM; Garambois K; Hommel M; Remy C
Rev Neurol (Paris); 2014 Dec; 170(12):779-98. PubMed ID: 25459115
[TBL] [Abstract][Full Text] [Related]
6. Biotherapies in brain diseases: for who, when and how?
Remy P
Rev Neurol (Paris); 2014 Dec; 170(12):725-6. PubMed ID: 25459123
[No Abstract] [Full Text] [Related]
7. Immunotherapy in autoimmune neuromuscular disorders.
Gold R; Dalakas MC; Toyka KV
Lancet Neurol; 2003 Jan; 2(1):22-32. PubMed ID: 12849298
[TBL] [Abstract][Full Text] [Related]
8. [Biotherapies: a revolution on the move].
Braun S
Med Sci (Paris); 2019 Mar; 35 Hors série n° 1():8-12. PubMed ID: 30943153
[No Abstract] [Full Text] [Related]
9. Biological Therapies of Immunologic Diseases: Strategies for Immunologic Interventions.
Polk BI; Rosenwasser LJ
Immunol Allergy Clin North Am; 2017 May; 37(2):247-259. PubMed ID: 28366475
[TBL] [Abstract][Full Text] [Related]
10. [Not Available].
Paintaud G; Tonelli D; Postaire E;
Therapie; 2007; 62(3):229-34. PubMed ID: 27393407
[No Abstract] [Full Text] [Related]
11. Ion channel and striational antibodies define a continuum of autoimmune neuromuscular hyperexcitability.
Vernino S; Lennon VA
Muscle Nerve; 2002 Nov; 26(5):702-7. PubMed ID: 12402293
[TBL] [Abstract][Full Text] [Related]
12. RNA-targeting approaches for neuromuscular diseases.
Le Roy F; Charton K; Lorson CL; Richard I
Trends Mol Med; 2009 Dec; 15(12):580-91. PubMed ID: 19906562
[TBL] [Abstract][Full Text] [Related]
13. Biotherapies in multiple sclerosis: a step toward remyelination and neuroprotection?
Dubessy AL; Zujovic V; Papeix C; Stankoff B
Rev Neurol (Paris); 2014 Dec; 170(12):770-8. PubMed ID: 25459127
[TBL] [Abstract][Full Text] [Related]
14. [Request for a compassionate use of biotherapies in oncology].
Hauteville D
Bull Cancer; 2006 Nov; 93(11):1152-4. PubMed ID: 17145586
[TBL] [Abstract][Full Text] [Related]
15. Proteomics of skeletal muscle differentiation, neuromuscular disorders and fiber aging.
Ohlendieck K
Expert Rev Proteomics; 2010 Apr; 7(2):283-96. PubMed ID: 20377394
[TBL] [Abstract][Full Text] [Related]
16. A review: the use of rituximab in neuromuscular diseases.
Ibrahim H; Dimachkie MM; Shaibani A
J Clin Neuromuscul Dis; 2010 Dec; 12(2):91-102. PubMed ID: 21386778
[TBL] [Abstract][Full Text] [Related]
17. Restorative neurology of progressive neuromuscular disorders.
Dimitrijevic MR
Aust Paediatr J; 1988; 24 Suppl 1():100-3. PubMed ID: 3060067
[TBL] [Abstract][Full Text] [Related]
18. Advances in translational research in neuromuscular diseases.
Pleasure D
Arch Neurol; 2011 Apr; 68(4):429-33. PubMed ID: 21482923
[TBL] [Abstract][Full Text] [Related]
19. B cell-targeted therapy with rituximab and autoimmune neuromuscular disorders.
Stübgen JP
J Neuroimmunol; 2008 Nov; 204(1-2):1-12. PubMed ID: 18783837
[TBL] [Abstract][Full Text] [Related]
20. Selective manipulation of the immune response in vivo by monoclonal antibodies.
Seaman WE; Wofsy D
Annu Rev Med; 1988; 39():231-41. PubMed ID: 3285774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
